ITGAX and neoplasm: We then assessed by multiplexed immunohistochemistry (mIHC) the presence of tumor-infiltrating CD3+ (total T cells), Granzyme B+ (GZMB+, a proxy marker of cytotoxic T cells), FOXP3+ (marker of CD4+ regulatory T cells, Tregs), CD11c+ (myeloid cells), and the expression of PD-L1, by both immune/stromal and tumor cells of PF and PD (Fig. 3B–D and Supplementary Fig. 2B, C).